Betty Y.S. Kim

CTIM-40. IMMUNE PROFILING OF GBM TUMOR TISSUES COLLECTED LONGITUDINALLY FROM PATIENTS TREATED WITH AN ONCOLYTIC VIRUS

Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target

Phase 2 of extracellular RNA communication consortium charts next-generation approaches for extracellular RNA research

Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity

Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016

The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update

Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation

On the issue of transparency and reproducibility in nanomedicine

Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade

Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery

Tumor Vasculatures: A New Target for Cancer Immunotherapy

Publisher Correction: On the issue of transparency and reproducibility in nanomedicine

Publisher Correction: On the issue of transparency and reproducibility in nanomedicine

Increased vessel perfusion predicts the efficacy of immune checkpoint blockade

The Reciprocity between Radiotherapy and Cancer Immunotherapy

IMMU-14. THERAPEUTIC MODULATION OF THE PHAGOCYTIC AXIS SPARKS ANTI-TUMOR CD8 T CELL RESPONSES IN GLIOBLASTOMA

Designing nanomedicine for immuno-oncology

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma

Lessons from immuno-oncology: a new era for cancer nanomedicine?

Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes